SCHEMBL6324472

SCHEMBL6324472

CCOc1cc(OCC)c2c(c1)OC(c1ccc(OC)cc1)C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROR1 Q01973 1/20 0.51
ALDH1A1 P00352 6/20 0.46
MEN1 O00255 2/20 0.40
HTT P42858 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ABCB1 P08183 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LMNA P02545 1/20 0.39
CBS P35520 1/20 0.39
CYP3A4 P08684 3/20 0.38
CYP19A1 P11511 2/20 0.38
MAOB P27338 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2491951 0.88 ROR1 (0.39) ROR1ALDH1A1NPSR1LMNAKDM4E
SCHEMBL30725970 0.84 ALDH1A1 (0.58) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL10054661 0.84 ALDH1A1 (0.58) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL6324673 0.84 ALDH1A1 (0.58) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL5788017 0.81 ALDH1A1 (0.46) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL5791797 0.81 ALDH1A1 (0.47) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL15077679 0.77 ALDH1A1 (0.47) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL15077681 0.77 ALDH1A1 (0.47) ROR1ALDH1A1MEN1HTTKMT2A
SCHEMBL2629461 0.76 ALDH1A1 (0.55) ALDH1A1MAPTABCB1CYP3A4CYP19A1
SCHEMBL30966448 0.76 ALDH1A1 (0.55) ALDH1A1MAPTABCB1CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943182-B2 Cyclopentabenzofuran derivatives and their use BAYER AKTIENGESELLSCHAFT (DE) 2005-09-13 US disclosed
US-20030144334-A1 Cyclopentabenzofuran derivatives and their use GUARNIERI WALTER (DE) 2003-07-31 US disclosed
EP-1102761-B1 CYCLOPENTABENZOFURAN DERIVATIVES AND THEIR USE BAYER AG (DE) 2003-01-29 EP disclosed
US-6420393-B1 NUCLEAR FACTOR .KAPPA.B-DEPENDENT DISEASE SELECTED FROM THE GROUP CONSISTING OF INFLAMMATORY DISEASES, IMMUNOLOGICAL DISORDERS, SEPTIC SHOCK, TRANSPLANT REJECTION, RADIATION DAMAGE, REPERFUSION INJURIES AFTER ISCHEMIA, STROKE OR BAYER AKTIENGESELLSCHAFT (DE) 2002-07-16 US disclosed
EP-1102761-A2 CYCLOPENTABENZOFURAN DERIVATIVES AND THEIR USE Bayer Aktiengesellschaft (DE) 2001-05-30 EP disclosed
WO-2000008007-A2 CYCLOPENTABENZOFURAN DERIVATIVES AND THEIR USE BAYER AKTIENGESELLSCHAFT (DE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144334-A1 Cyclopentabenzofuran derivatives and their use NFKBIA, IKBKG, NFKB1 ROR1 3665/4885ALDH1A1 2159/4885MEN1 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.